AGT and cardiac hypertrophy: A previous study further established that DPP3 administration to angiotensin II (Ang II)–induced hypertensive mice could significantly diminish systolic blood pressure, cardiac hypertrophy, and myocardial fibrosis to an extent at par with the effect of the angiotensin receptor blocker candesartan.